Next generation sequencing (NGS) is quickly gaining regulatory agencies' acceptance as a sensitive and un-biased detection method for adventitious agents. Avance Biosciences is positioned to be a strategic partner with our pharmaceutical clients in establishing this powerful tool for testing viral contaminants in cell substrates and biological products.
Working closely with a major US-based pharmaceutical client, Avance Biosciences developed its NGS viral detection work flow that is capable of detecting various viruses (dsDNA, ssDNA, ssRNA, and dsRNA viruses) at low concentrations. Avance Biosciences has since successfully completed two GMP-level viral detection projects for this client in support of their viral vaccine applications.
And more recently, Avance Biosciences has also participated in a collaborative study organized by National Institute for Biological Standards and Control (NIBSC) to compare the abilities of NGS methods to identify viruses in a reference material. Avance Biosciences’ data are consistent with the results of the majority of the participating labs and correlates well with the qPCR data released by NIBSC after NGS data submission.
- Testing adventitious viruses in biological products
- Raw materials
- Final products
- Matrix with viral spike-in
- Testing adventitious viruses in cell substrates
- Cell culture
- Supernatant after cell pre
Need more info?
We are dedicated to timely, high-quality service from the start of your project to the finish. Send us a quick message with your questions to find out what Avance can do for you.
Ready to get started?
Give us a little background on your needs and the goals of your project, and we’ll send a preliminary quote including: tasks, deliverables and a no-obligation cost estimate.